Policy Developments - Shanghai aims to vigorously cultivate and develop future industries such as brain-computer interfaces and fourth-generation semiconductors, as stated in the government work report presented at the Shanghai Municipal People's Congress [1] Drug and Medical Device Approvals - Novartis announced that its innovative biological drug Cosentyx (secukinumab) has received approval from the National Medical Products Administration in China for a new indication to treat active non-radiographic axial spondyloarthritis in adults who have had an inadequate response to non-steroidal anti-inflammatory drugs [2] - Hualan Biological announced that its recombinant Exendin-4-Fc fusion protein injection (HL08) has received clinical trial approval for use in adult patients with obesity or overweight, expanding its indications beyond type 2 diabetes [3] - Bibet's BEBT-701, a globally first AGT/PCSK9 dual-target siRNA drug, has received approval for clinical trials to treat mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [4] - Zhifei Biological's mRNA vaccine for shingles has received clinical trial approval from the National Medical Products Administration [5] Financial Data - Yaokang Biological reported a total revenue of 793 million yuan for 2025, a year-on-year increase of 15.49%, and a net profit of 144 million yuan, reflecting a growth of 31.49% [6] Industry Developments - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization rights agreement for the Inusimab injection, paying an authorization fee of 80 million yuan [7][8] - Insilico Medicine announced it received a milestone payment of 39 million HKD from Menarini after the MEN2501 project completed its first patient dosing in Phase I clinical trials [9] - WuXi Biologics has signed a licensing and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T cell engager, which will be used to treat B cell-mediated autoimmune diseases [10]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696) 自願公告 英矽智能獲美納里尼 3,900 萬港元里程碑付款， 合作項目 MEN2501 完成首例患者給藥 本公告由英矽智能（「本公司」，連同其附屬公司統稱「本集團」或「英矽智能」）自 願作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，英矽智能對外授權給美納里尼集團（「美納 里尼」）的MEN2501項目已在I期臨床試驗中完成首例患者給藥，根據雙方合作協 議，英矽智能獲得由美納里尼支付的約3,900萬港元的最新里程碑付款。 關於MEN2501(ISM9682) 1 前瞻性陳述 概不保證本公告所載關於本集團業務發展之任何前瞻性聲明，或任何事宜將可達 成、將真實發生或將實現或屬完整或準確。本公告所披露 ...